BioXcel Therapeutics, Inc. (BTAI)

Market Cap	33.02M +352.4%
Revenue (ttm)	752,000 -67.0%
Net Income	-68.21M
EPS	-9.09
Shares Out	21.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	695,816
Open	1.600
Previous Close	1.600
Day's Range	1.490 - 1.620
52-Week Range	1.170 - 8.080
Beta	0.23
Analysts	Strong Buy
Price Target	23.25 (+1,439.74%)
Earnings Date	May 11, 2026

About BTAI

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 8, 2018
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: BTAI
• Website: https://www.bioxceltherapeutics.com

Financial Performance

In 2024, BioXcel Therapeutics's revenue was $2.27 million, an increase of 64.20% compared to the previous year's $1.38 million. Losses were -$59.60 million, -66.71% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price target is $23.25, which is an increase of 1,439.74% from the latest price.

Price Target

$23.25

(1,439.74% upside)

Analyst Consensus: Strong Buy